GCP
ACET icon

GSA Capital Partners’s Adicet Bio ACET Stock Holding History

GSA Capital Partners’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-17,763
Closed -$150K – 1668
2025
Q4 		$150K Buy
+17,763
New +$196K 0.01% 1475
2025
Q1 		– Sell
-1,048
Closed -$16K – 1599
2024
Q4 		$16K Sell
1,048
-1,403
-57% -$26.5K ﹤0.01% 1556
2024
Q3 		$56K Buy
2,451
+1,513
+161% +$33.9K ﹤0.01% 1516
2024
Q2 		$18K Buy
+938
New +$25.1K ﹤0.01% 1577
2024
Q1 		– Sell
-1,292
Closed -$39K – 1561
2023
Q4 		$39K Sell
1,292
-7,594
-85% -$166K ﹤0.01% 1425
2023
Q3 		$195K Buy
8,886
+2,325
+35% +$82.1K 0.02% 1292
2023
Q2 		$255K Buy
6,561
+3,915
+148% +$346K 0.03% 1138
2023
Q1 		$244K Buy
2,646
+1,235
+88% +$155K 0.02% 1144
2022
Q4 		$202K Sell
1,411
-254
-15% -$63.4K 0.03% 1178
2022
Q3 		$379K Buy
+1,665
New +$423K 0.05% 777

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

GSA Capital Partners's ACET Position: Q1 2026 in Review

GSA Capital Partners sold out of Adicet Bio (ACET) in Q1 2026, closing a stake of 17,763 shares — an estimated $150K sold.

GSA Capital Partners first reported a position in ACET in Q3 2022 and held it in 10 quarters. The position peaked at $379K in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • GSA Capital Partners reported no remaining Adicet Bio position as of Q1 2026 after selling out during the quarter.
  • GSA Capital Partners sold 17,763 Adicet Bio shares in Q1 2026, an estimated $150K.
  • GSA Capital Partners first reported a position in Adicet Bio in Q3 2022 and held it in 10 quarters.
  • GSA Capital Partners's Adicet Bio position peaked at $379K in Q3 2022.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.